Existing investors Hewlett Packard Enterprise, GV, Intel Capital, SingTel Innov8 and M12 all participated as the cybersecurity services provider took its total funding to $112m.

Existing backer Ligand took part in a series C round that will fund late-stage clinical trials for Palvella Therapeutics' rare genetic disease drug candidates.

Q32 Bio has launched with $46m from investors including Sanofi Ventures and Children’s Hospital Colorado to target autoimmune and inflammatory diseases.

GCV Powerlist member Natalie Hwang has departed from Simon Property Group where she oversaw its investment arm for nearly five years, and set up a growth equity firm.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Allianz Life Ventures invested in the artificial intelligence software developer as part of a round that took its total funding to $14.5m.

Blue Venture Fund and McKesson Ventures returned to reinvest in the cancer care analysis platform through a round that almost doubled its overall funding.

Existing backer Experian Ventures was among the investors as the text message-based financial education provider raised $12.6m.

The diabetes treatment developer, which counts WL Gore and Johnson & Johnson as investors, has raised a further $27m for its latest round.

Philips Health Technology Ventures and UnityPoint Health Ventures have taken part in a $16.7m round for the telehealth technology provider.